» Articles » PMID: 36793753

Predicting the Survival Benefit of Liver Transplantation in HBV-related Acute-on-chronic Liver Failure: an Observational Cohort Study

Abstract

Background: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients.

Methods: Hospitalized patients with acute deterioration of HBV-related chronic liver disease (n = 4577) from the Chinese Group on the Study of Severe Hepatitis B (COSSH) open cohort were enrolled to evaluate the performance of five commonly used scores for predicting the prognosis and transplant survival benefit. The survival benefit rate was calculated to reflect the extended rate of the expected lifetime with vs. without LT.

Findings: In total, 368 HBV-ACLF patients received LT. They showed significantly higher 1-year survival than those on the waitlist in both the entire HBV-ACLF cohort (77.2%/52.3%, p < 0.001) and the propensity score matching cohort (77.2%/27.6%, p < 0.001). The area under the receiver operating characteristic curve (AUROC) showed that the COSSH-ACLF II score performed best (AUROC 0.849) at identifying the 1-year risk of death on the waitlist and best (AUROC 0.864) at predicting 1-year outcome post-LT (COSSH-ACLFs/CLIF-C ACLFs/MELDs/MELD-Nas: AUROC 0.835/0.825/0.796/0.781; all p < 0.05). The C-indexes confirmed the high predictive value of COSSH-ACLF IIs. Survival benefit rate analyses showed that patients with COSSH-ACLF IIs 7-10 had a higher 1-year survival benefit rate from LT (39.2%-64.3%) than those with score <7 or >10. These results were prospectively validated.

Interpretation: COSSH-ACLF IIs identified the risk of death on the waitlist and accurately predicted post-LT mortality and survival benefit for HBV-ACLF. Patients with COSSH-ACLF IIs 7-10 derived a higher net survival benefit from LT.

Funding: This study was supported by the National Natural Science Foundation of China (No. 81830073, No. 81771196) and the National Special Support Program for High-Level Personnel Recruitment (Ten-thousand Talents Program).

Citing Articles

Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.

Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A Hepatol Int. 2025; 19(1):1-69.

PMID: 39961976 PMC: 11846769. DOI: 10.1007/s12072-024-10773-4.


Clinical Utility of the Trajectory of Serum Bilirubin and International Normalized Ratio Values in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.

Song Y, Fu X, Yan S, Qi R, Zhou Y, Liang J Int J Gen Med. 2025; 18:643-658.

PMID: 39935709 PMC: 11812449. DOI: 10.2147/IJGM.S490328.


Outcome Predictors of Acute-on-Chronic Liver Failure: A Narrative Review.

Batra N, Gaidhane S, Kumar S, Acharya S Cureus. 2024; 16(6):e61655.

PMID: 38966452 PMC: 11223737. DOI: 10.7759/cureus.61655.


Interleukin-8 predicts short-term mortality in acute-on-chronic liver failure patients with hepatitis B-related-related cirrhosis background.

Liu L, Chen P, Xiao N, Liu Q, Zhu X Ann Med. 2023; 55(2):2287708.

PMID: 38052052 PMC: 10836280. DOI: 10.1080/07853890.2023.2287708.


Acute-on-chronic liver failure: far to go-a review.

Luo J, Li J, Li P, Liang X, Hassan H, Moreau R Crit Care. 2023; 27(1):259.

PMID: 37393351 PMC: 10315037. DOI: 10.1186/s13054-023-04540-4.


References
1.
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7):1426-37, 1437.e1-9. DOI: 10.1053/j.gastro.2013.02.042. View

2.
Merion R, Schaubel D, Dykstra D, Freeman R, Port F, Wolfe R . The survival benefit of liver transplantation. Am J Transplant. 2005; 5(2):307-13. DOI: 10.1111/j.1600-6143.2004.00703.x. View

3.
Hernaez R, Liu Y, Kramer J, Rana A, El-Serag H, Kanwal F . Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020; 73(6):1425-1433. PMC: 10424237. DOI: 10.1016/j.jhep.2020.06.005. View

4.
Li J, Liang X, You S, Feng T, Zhou X, Zhu B . Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure. J Hepatol. 2021; 75(5):1104-1115. DOI: 10.1016/j.jhep.2021.05.026. View

5.
. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2015; 64(2):433-485. DOI: 10.1016/j.jhep.2015.10.006. View